Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

サイズ 価格(税別)  
JPY 44820.00

カスタマーフィードバック(3)

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
ターゲット
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MWjDfZRwfG:6aXRCpIF{e2G7 MX20PEBp MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NHWtNFYh|ryPLh?= NGHi[ZczOTN6OEG5NS=>
human colon cancer cell line (LoVo cells) MVvQdo9tcW[ncnH0bY9vKGG|c3H5 NG\yUppCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPvcI9vKGOjbnPldkBk\WyuIHzpcoUhMEyxVn:gZ4VtdHNrIIXzbY5oKE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0v MXexNVU6OTVyNR?=
human LoVo cells MWPQdo9tcW[ncnH0bY9vKGG|c3H5 NIXwdpU1QCC2bzC3NkBp MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxVn:gZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfS=> NUX0PVhCOjJzOEK5Nlk>
P19 cells MVLGeY5kfGmxbjDhd5NigQ>? M{LwWmlvcGmkaYTpc44hd2ZiUHzheIVt\XRvZHXybZZm\CCpcn;3eIgh\mGldH;yJJJm[2WydH;yJIlvKFBzOTDj[YxteyxiSVO1NF0xNjByMjFOwG0v NH7m[mQyPTd5MUSxPS=>
human BJ cells NEPBUVREgXSxdH;4bYPDqGG|c3H5 MWm3NkBp M{jTSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTBwMECyJO69VS5? M4jYfFIzQTJzMEix
human HT-29 cells M2fFXmZ2dmO2aX;uJIF{e2G7 MWKyJIg> NX;YOFNVTW[oZXP0JI9vKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFIhcHK|IIXzbY5oKEqFLUGgd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHHzd4F6 M1;mS|IyPDJ6M{e1
human A549 cells M2LmbWN6fG:2b4jpZ:Kh[XO|YYm= MUG3NkBp NHraN|REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJI1mfGixZB?= NWGwXY9pOTh2OES3O|U>
human HT-29 cells NGTqc5NHfW6ldHnvckBie3OjeR?= NVHUWIRpUW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCxdHXueIlidCCrbjDoeY1idiCKVD2yPUBk\WyuczD1d4lv\yCMQ{Gg[JlmKHO2YXnubY5oKGK7IH\seY9z\XOlZX7j[UBxdGG2ZTDy[YFl\XJiYYPzZZktKEmFNUC9Nk42KG6P NYPvTohqOjF3MUOyPVM>
human HT-29 cells NFLpTHJHfW6ldHnvckBie3OjeR?= NVjHfWd6OiCq NVn2c|lHUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBz\WS3Y4Tpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwh[W[2ZYKgNkBpenNiYomgeZNqdmdiSlOxJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDj[YxtNWKjc3XkJIF{e2G7LDDFR|UxRTJwNjDuUU4> MUiyNVk4OzFyMR?=
Sf9 cells MoiySpVv[3Srb36gZZN{[Xl? MVTJcohq[mm2aX;uJI9nKGi3bXHuJHN6cyCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzMEBKSzVyPUOgcm0v M3T6T|E5QDJ|N{i0
human HUVEC M3TmXXBzd2yrZnXyZZRqd25iYYPzZZk> NIrvWVM1QCC2bzC3NkBp M4PIXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMh[W[2ZYKgOFghfG9iN{KgbJJ{KGK7IF3UWEBie3OjeR?= MnvtNlIyQDJ7Mkm=
P19 cells NIPYT41HfW6ldHnvckBie3OjeR?= Mn;ITY5pcWKrdHnvckBw\iCScn;0[YlvKEurbnHz[UBCKGmwIGCxPUBk\WyuczygTWM2OD12IH7NMi=> NHfDTZYyPTd5MUSxPS=>
Sf9 cells MXnGeY5kfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgcYlvKGK7IFXMTXNCKGmwIIDy[ZNmdmOnIH;mJFEhfW2xbD;MJGFVWA>? MWmxO|MyPTh3Mx?=
Sf21 cells MUfGeY5kfGmxbjDhd5NigQ>? M2\2OWlvcGmkaYTpc44hd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczygTWM2OD14IH7NMi=> MmOwNVcxQDhyNUm=
human colon carcinoma cell line HCT116 NH;GSnBHfW6ldHnvckBie3OjeR?= NUnFXFFlS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> MoGwNVU2Ozd|NEW=
human ST486 cells NGnqSVlRem:uaX\ldoF1cW:wIHHzd4F6 MYG0PEB1dyB5MjDo MmrsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVES4OkBk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVchdk1w Mmr2NlIyQDJ7Mkm=
human MDA-MB-231 cells NGHhcZREgXSxdH;4bYPDqGG|c3H5 M1;SbFczKGh? M2P5Z2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVcvOSCwTT6= Mor2NVg1QDR5N{W=
P19 cells NGTuXo9HfW6ldHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKEO7Y3zpck1l\XCnbnTlcpQhc2mwYYPlJFEhcW5iUEG5JINmdGy|LDDJR|UxRThibl2u NVKxU5VCOTV5N{G0NVk>
human DLD1 cells MX7Qdo9tcW[ncnH0bY9vKGG|c3H5 NWTBTo1YPDhvN{KgbC=> NGPENYtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTMSFEh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF06KG6PLh?= NEWwW4IzOjF6MkmyPS=>
insect cells M{TWW2Z2dmO2aX;uJIF{e2G7 NETCNYRKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDpcVEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{BjgSCKVGLGMEBKSzVyPUGwJI5ONg>? MWWxPVE4QTB5Nh?=
V79 MZ cells M{i4XmZ2dmO2aX;uJIF{e2G7 MoDPTY5pcWKrdHnvckBw\iCqdX3hckBidGSxc4Tldo9v\SC|eX70bIF{\SCneIDy[ZN{\WRiaX6gWlc6KE2cIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[Wymb4P0[ZJwdmVic4nueIhme2m|LDDJR|UxRTFzIH7NMi=> Mm\SNlQ1OjJ3MUm=
P19 cells M1r3bmZ2dmO2aX;uJIF{e2G7 MWPJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> MlO3NVU4PzF2MUm=
Sf9 cells MXzGeY5kfGmxbjDhd5NigQ>? NFXHdpUzOCCvaX7z NV7qZ5VyUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAzOCCvaX7zJIJ6KEWOSWPBJIlvKHC{ZYPlcoNmKG:oIEGgeY1wdC:OIFHUVEwhUUN3ME2xOUBvVS5? MlXrNVc{OTV6NUO=
human PBMC MVHGeY5kfGmxbjDhd5NigQ>? NIj5O2szPCCq NH7iVpBUfXCycnXzd4lwdiCxZjDJUFIheHKxZIXjeIlwdiCrbjDoeY1idiCSQl3DJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiSVO1NF0yPiCwTT6= NFrnbVQyQDV6NUC0Oi=>
human A549 cells Ml;RR5l1d3SxeHnjxsBie3OjeR?= M4TDXFQ5KGh? MmC5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5JEwhUUN3ME2yNEBvVS5? NUm0XJAyOjV6MkW5N|Q>
human CEM cells M3\y[2N6fG:2b4jpZ:Kh[XO|YYm= MnnrO|IhcA>? M1rXNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1{MzDuUU4> NWPrS4JLOjJ7MkGwPFE>
human HeLa cells M3XyWWN6fG:2b4jpZ:Kh[XO|YYm= M1LK[FQ5KGh? M3PMW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yOUBvVS5? M4TGclI2QDJ3OUO0
human PC3 cells M{DxdGN6fG:2b4jpZ:Kh[XO|YYm= MU[0PEBp MknNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUOxJI5ONg>? NUPQUlQ{OjV6MkW5N|Q>
human SF268 cells MXTDfZRwfG:6aXRCpIF{e2G7 M3nO[VQ5KGh? NV[3SZc1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= M{\tUVIyPTF|Mkm0
human MCF7 cells M1PoRWN6fG:2b4jpZ:Kh[XO|YYm= M4rmNVQ5KGh? MnzlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUWwJI5ONg>? NVn6V4J7OjF|OEixPVE>
HEK293 cells NXz3TZpUS3m2b4TvfIlkyqCjc4PhfS=> NEDwTGs4OiCq MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmekeubzDhd5NigSxiSVO1NF02PiCwTT6= MUKyOFc3OzJ4Mh?=
HUE cells M1uyWWZ2dmO2aX;uJIF{e2G7 MV65NEBucW6| NVnyTHhJUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gTHVGKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25idILlZZRm\CCob4KgPVAhdWmwczDi[YZwemViVlXHSkBkcGGubHXu[4Uh[nliRVzJV2EtKEmFNUC9O|Ahdk1w Mo\oNlAyPzBzNkO=
human A431 cells MWDDfZRwfG:6aXRCpIF{e2G7 MkHJNlQhKGh? NVOxSI5jS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR|MTDj[YxteyCjZoTldkAzPCCqcoOgeZNqdmdiQX7u[ZhqdiCYZV\JWGMweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{BjgSCPVGSgZZN{[XluIFnDOVA:PzBibl2u M3r6XVIzPTRzMEWx
human Jurkat cells Mof3VJJwdGmoZYLheIlwdiCjc4PhfS=> NW\xUG45SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBLSUt|IHX4dJJme3OrbnegTWwzNXO2aX31cIF1\WRiaIXtZY4hUnW{a3H0JINmdGy|LDDJR|UxRTdzIH7NMi=> Ml;sNVk1Ojd{MEO=
HEK293 cells MWHGeY5kfGmxbjDhd5NigQ>? NHK2RWVKdmirYnn0bY9vKG:oIFnMMVghemWuZXHz[UBjgSCKRVuyPVMh[2WubIOg[ZhxemW|c3nu[{BRU0NvYnX0ZVItKEmFNUC9O|chdk1w NHPTfJQyPTd5MUSxPS=>
human KE-97 cells NWfiXoZiS3m2b4TvfIlkyqCjc4PhfS=> MkHvO|IhcA>? MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLSU06PyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE{KM7:TT6= NVqydXd2OjR|MkiyPFM>
human CHOK1 cells M{D5[WN6fG:2b4jpZ:Kh[XO|YYm= MYO0PEBp NEfUdI9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEUE:NMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5zMzFOwG0v NH\ubmUzOTVzM{K5OC=>
mouse NIH/3T3 cells M1TmTGN6fG:2b4jpZ:Kh[XO|YYm= MWS5OkBp NV[1OmE5S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v NWTWOXBkOjR|NkG1NlE>
human A2780 cells MnXyR5l1d3SxeHnjxsBie3OjeR?= MVW5OkBp Mk\CR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NEnE[G4zPDN4MUWyNS=>
human 8505C cells NWDQS2duS3m2b4TvfIlkyqCjc4PhfS=> NILhZVI6PiCq NInpUXNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA5PTB3QzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u NIPmcHgzPDN4MUWyNS=>
human 518A2 cells MXHDfZRwfG:6aXRCpIF{e2G7 MXy5OkBp MkToR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gOVE5STJiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOiEQvF2u M{DYWFI1OzZzNUKx
human HuH7 cells M1fE[WN6fG:2b4jpZ:Kh[XO|YYm= M{S2PFczKGh? NWnJW|NSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|IN88UU4> NEDWWXYzPDN{OEK4Ny=>
FL5.12-Akt1 cells NYHqRXJvWHKxbHnm[ZJifGmxbjDhd5NigQ>? MojZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDGUFUvOTJvQXv0NUBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9NE4zQSEQvF2u M1\0d|E3PDB|NkK2
human MiaPaCa-2 cells NGjscGNRem:uaX\ldoF1cW:wIHHzd4F6 MlzrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPaXHQZWNiNTJiY3XscJMtKEmFNUC9NE4{PyEQvF2u NHT0THIyPjRzM{e4NC=>
human BGC823 cells MlPGR5l1d3SxeHnjxsBie3OjeR?= NH\melI4OiCq M3nlS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6IN88UU4> MkHrNlQ{Ojh{OEO=
human MCF7 cells M2PEWWN6fG:2b4jpZ:Kh[XO|YYm= NVHUNlM4QTZiaB?= NY\LNJVyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPCEQvF2u NI\CVGQzPDN4MUWyNS=>
human A549 cells MUDDfZRwfG:6aXRCpIF{e2G7 MkfhPVYhcA>? NF;2NnVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE43KM7:TT6= Mkm0NlQ{PjF3MkG=
HEK293 cells NYjJVpZUS3m2b4TvfIlkyqCjc4PhfS=> MkHhR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|LDDFR|UxRTJizszNMi=> M2rJcVI2OzF4M{G3
human Raji cells  MX\DfZRwfG:6aXRCpIF{e2G7 NV33SpJpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6= Ml7rNlU{OTZ|MUe=
human HepG2 cells NInhZWpEgXSxdH;4bYPDqGG|c3H5 NVHrUG5lS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVA:OiEQvF2u MmjrNlU{OTZ|MUe=
human BJ cells MYfDfZRwfG:6aXRCpIF{e2G7 NEHsU2JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{whTUN3ME2yJO69VS5? MkLwNlU{OTZ|MUe=
human U937 cells NYfkeJRUS3m2b4TvfIlkyqCjc4PhfS=> NEL1RZVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{NCCLQ{WwQVIh|ryPLh?= M1rhNlE4ODh6ME[3

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞試験:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物試験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
in solvent
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PKCシグナル伝達経路

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID